Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 7, 2003, Pages 1204-1210

  Li, Lijun ^b   Lee, Edward W ^b   Ji, Hong ^b   Zukowska, Zofia ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

Atherosclerosis; Neointima; Neuropeptide Y; NPY receptors; Restenosis

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; H4099; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR ANTAGONIST; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; DRUG PROTEIN BINDING; IMMUNOREACTIVITY; INTIMA; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK FACTOR; THROMBOCYTE;

ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON; ANIMALS; ARTERIOSCLEROSIS; BLOOD PLATELETS; CAROTID ARTERY, COMMON; CAROTID STENOSIS; ENDOTHELIUM, VASCULAR; MALE; NEUROPEPTIDE Y; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; RECURRENCE; TUNICA INTIMA; UP-REGULATION;

EID: 0038159673     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000071349.30914.25     Document Type: Article

References (48)

1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516.
2. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
3. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
5. Longhurst JC. Coronary arteriolar vasoconstriction in myocardial ischaemia: reflexes, sympathetic nervous system, catecholamines. Eur Heart J. 1990;11(suppl B):43-52.
6. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000;35:S1-S7.
7. Teeters JC, Erami C, Zhang H, Faber JE. Systemic alpha 1A-adrenoceptor antagonist inhibits neointimal growth after balloon injury of rat carotid artery. Am J Physiol Heart Circ Physiol. 2003;284:H385-H392.
8. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002;22:364-373.
9. Zukowska-Grojec Z, Wahlestedt C. Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Wahlestedt C, eds. The Biology of Neuropeptide Y and Related Peptides. Totowa, New Jersey: Human Press; 1993.
10. Erlinge D, Ekman R, Thulin T, Edvinsson L. Neuropeptide Y-like immunoreactivity and hypertension. J Hypertens. 1992;10:1221-1225.
11. Grundemar L. Multiple receptors and multiple actions. In: Grundemar L, Bloom S, eds. Neuropeptide Y and Drug Development. San Diego: Academic Press; 1997.
12. Zukowska-Grojec Z, Dayao EK, Karwatowska-Prokopczuk E, Hauser GJ, Doods HN. Stress-induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors. Am J Physiol. 1996;270: H796-H800.
13. Zukowska-Grojec Z, Neuropeptide Y. Implications in vascular remodeling and novel therapeutics. Drug News Perspect. 1997;10:587-595.
14. Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z. Neuropeptide Y and vascular growth: role of Y1 and Y5 receptors and adrenergic activation. Can J Physiol Pharmacol. 2003;81:177-185.
15. Shigeri Y, Fujimoto M. Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett. 1993;149:19-22.
16. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS. Neuropeptide Y. A novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83:187-195.
17. Schwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol. 1994;51: 53-61.
18. Myers AK, Farhat MY, Vaz CA, Keiser HR, Zukowska-Grojec Z. Release of immunoreactive-neuropeptide by rat platelets. Biochem Biophys Res Commun. 1988;155:118-122.
19. Ericsson A, Schalling M, McIntyre KR, Lundberg JM, Larhammar D, Seroogy K, Hokfelt T, Persson H. Detection of neuropeptide Y and its mRNA in megakaryocytes: enhanced levels in certain autoimmune mice. Proc Natl Acad Sci U S A. 1987;84:5585-5589.
20. Ericsson A, Hemsen A, Lundberg JM, Persson H. Detection of neuropeptide Y-like immunoreactivity and messenger RNA in rat platelets: the effects of vinblastine, reserpine, and dexamethasone on NPY expression in blood cells. Exp Cell Res. 1991;192:604-611.
21. Mentlein R, Dahms P, Grandt D, Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept. 1993;49:133-144.
22. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis. 2001; 159:145-151.
23. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J, Laakso M, Uusitupa MIJ. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associates with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Memb. 2000;85:2266-2269.
24. Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu WS, Li Z, Stetler-Stevenson W, Nater C, Froehlich JP, Lakatta EG, Cheng L. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation. 1998;97:82-90.
25. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther. 1995;275:136-142.
26. Criscione L, Rigollier P, Batzl-Hartmann C, Rueger H, Stricker-Krongrad A, Wyss P, Brunner L, Whitebread S, Yamaguchi Y, Gerald C, Heurich RO, Walker MW, Chiesi M, Schilling W, Hofbauer KG, Levens N. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest. 1998;102:2136-2145.
27. Zukowska-Grojec Z, Marks ES, Haass M. Neuropeptide Y is a potent vasoconstrictor and a cardiodepressant in rat. Am J Physiol. 1987;253:H1234-H1239.
28. Underhill CB, Zhang L. Analysis of hyaluronan using biotinylated hyaluronan-binding proteins. Methods Mol Biol. 2000:137:441-447.
29. Erlinge D, Yoo H, Edvinsson L, Reis DJ, Wahlestedt C. Mitogenic effects of ATP on vascular smooth muscle cells vs other growth factors and sympathetic cotransmitters. Am J Physiol. 1993;265:H1089-H1097.
30. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep. 1999;19:51-71.
31. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Up-regulation of "clearance" receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail. 2001;3:407-414.
32. Ericsson A, Larhammar D, McIntyre KR, Persson H. A molecular genetic approach to the identification of genes expressed predominantly in the neuroendocrine and immune systems. Immunol Rev. 1987;100:261-277.
33. Myers AK, Farhat MY, Shen GH, Debinski W, Wahlestedt C, Zukowska-Grojec Z. Platelets as a source and site of action for neuropeptide Y. Ann N Y Acad Sci. 1990;611:408-411.
34. Zukowska-Grojec Z, Golczynska M, Shen GH, Torres-Duarte A, Haass M, Wahlestedt C, Myers AK. Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr Nephrol. 1993;7:845-852.
35. Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease. Am J Physiol. 1997;273:H2091-H2104.
36. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297:1176-1179.
37. Pernerstorfer T, Stohlawetz P, Kapiotis S, Eichler HG, Jilma B. Partial inhibition of nitric oxide synthase primes the stimulated pathway of vWF-secretion in man. Atherosclerosis. 2000;148:43-47.
38. Ghersi G, Chen W, Lee EW, Zukowska Z. Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides. 2001;22:453-458.
39. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002;277:29231-29241.
40. Ward MR, Tsao PS, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration. Arterioscler Thromb Vasc Biol. 2001;21:208-213.
41. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res. 1998;39:8-33.
42. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 1999;99:1733-1739.
43. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272:685-688.
44. De la Fuente M, Medina S, Del Rio M, Ferrandez MD, Hernanz A. Effect of aging on the modulation of macrophage functions by neuropeptides. Life Sci. 2000;67:2125-2135.
45. Turtzo LC, Marx R, Lane MD. Cross-talk between sympathetic neurons and adipocytes in coculture. Proc Natl Acad Sci USA. 2001;98: 12385-12390.
46. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. Am J Surg. 2002;183:430-434.
47. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 2000;407:94-98.
48. Mullins DE, Zhang X, Hawes BE. Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes. Regul Pept. 2002;105:65-73.